NL300286I1 - Beta-l-2'-desoxynucleosiden voor de behandeling van heparitis-b-virus - Google Patents

Beta-l-2'-desoxynucleosiden voor de behandeling van heparitis-b-virus

Info

Publication number: NL300286I1
Authority: NL; Netherlands
Prior art keywords: pentofuranonucleoside; deoxy; erythro; prodrug; hepatitis
Prior art date: 1998-08-10

Application number

NL300286C

Other languages

English (en)

Other versions

NL300286I2 (nl

Original Assignee

Idenix Cayman Ltd

Centre Nat Rech Scient

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-10

Filing date

2007-08-09

Publication date

2007-10-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26791121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300286(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-08-09 Application filed by Idenix Cayman Ltd, Centre Nat Rech Scient filed Critical Idenix Cayman Ltd

2007-10-01 Publication of NL300286I1 publication Critical patent/NL300286I1/nl

2008-01-02 Publication of NL300286I2 publication Critical patent/NL300286I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

NL300286C 1998-08-10 2007-08-09 Beta-L-2'-desoxynucleosiden voor de behandeling van Heparitis-B-virus. NL300286I2 (nl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9611098P	1998-08-10	1998-08-10
US13135299P	1999-04-28	1999-04-28
PCT/US1999/018149 WO2000009531A2 (en)	1998-08-10	1999-08-10	β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B

Publications (2)

Publication Number	Publication Date
NL300286I1 true NL300286I1 (nl)	2007-10-01
NL300286I2 NL300286I2 (nl)	2008-01-02

Family

ID=26791121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL300286C NL300286I2 (nl)	1998-08-10	2007-08-09	Beta-L-2'-desoxynucleosiden voor de behandeling van Heparitis-B-virus.

Country Status (22)

Country	Link
US (5)	US6395716B1 (nl)
EP (2)	EP1104436B1 (nl)
JP (2)	JP4294870B2 (nl)
KR (4)	KR100691737B1 (nl)
CN (3)	CN1257912C (nl)
AT (1)	ATE313550T1 (nl)
AU (1)	AU5475799A (nl)
BR (1)	BRPI9912896B8 (nl)
CA (1)	CA2340156C (nl)
CY (2)	CY2007017I1 (nl)
DE (2)	DE122007000062I1 (nl)
DK (3)	DK2415776T3 (nl)
ES (3)	ES2255295T3 (nl)
FR (1)	FR07C0046I2 (nl)
HK (3)	HK1034083A1 (nl)
LU (1)	LU91348I2 (nl)
MX (1)	MXPA01001507A (nl)
NL (1)	NL300286I2 (nl)
PT (2)	PT1431304E (nl)
RU (1)	RU2424016C2 (nl)
SG (1)	SG132498A1 (nl)
WO (1)	WO2000009531A2 (nl)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0831852B1 (en) *	1995-06-07	2006-11-29	Emory University	Nucleosides with anti-hepatitis b virus activity
US6444652B1 (en) *	1998-08-10	2002-09-03	Novirio Pharmaceuticals Limited	β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
DE122007000062I1 (de) *	1998-08-10	2007-12-20	Idenix Cayman Ltd	Beta-L-2'-deoxynukleoside für die Behandlung von Hepatitis-B-Virus
AU784374C (en) *	1999-11-12	2007-06-28	Pharmasset Inc	Synthesis of 2'-deoxy-L-nucleosides
EP1600451A3 (en)	1999-11-12	2008-09-10	Pharmasset, Inc.	Synthesis of 2'-deoxy-l-nucleosides
EA006181B1 (ru) *	2000-02-29	2005-10-27	Бристоль-Мейерз Сквибб Компани	Фармацевтический препарат на основе энтекавира и способ его получения
WO2001067772A2 (en) *	2000-03-09	2001-09-13	Videoshare, Inc.	Sharing a streaming video
US6822089B1 (en) *	2000-03-29	2004-11-23	Isis Pharmaceuticals, Inc.	Preparation of deoxynucleosides
JP2003532643A (ja) *	2000-04-13	2003-11-05	フアーマセツト・リミテツド	肝炎ウイルス感染症を治療するための３’−または２’−ヒドロキシメチル置換ヌクレオシド誘導体
MY164523A (en) *	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
AP2006003708A0 (en)	2000-05-26	2006-08-31	Idenix Cayman Ltd	Methods and compositions for treating flavivirusesand pestiviruses
US6787526B1 (en) *	2000-05-26	2004-09-07	Idenix Pharmaceuticals, Inc.	Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
ES2227203T3 (es)	2000-05-26	2005-04-01	Idenix (Cayman) Limited	Metodos para tratar la infeccion por el virus de la hepatitis delta con beta-1-2'-desoxinucleosidos.
US6875751B2 (en)	2000-06-15	2005-04-05	Idenix Pharmaceuticals, Inc.	3′-prodrugs of 2′-deoxy-β-L-nucleosides
MY141594A (en) *	2000-06-15	2010-05-14	Novirio Pharmaceuticals Ltd	3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
CN101250208B (zh) *	2000-11-29	2012-06-20	三井化学株式会社	L-核酸衍生物及其合成方法
CN102241720B (zh) *	2000-11-29	2014-01-29	三井化学株式会社	L-核酸衍生物及其合成方法
WO2003053360A2 (en)	2001-12-20	2003-07-03	Pharmassett Ltd.	Treatment of ebv and khsv infection and associated abnormal cellular proliferation
EP1458735A2 (en) *	2001-12-21	2004-09-22	Micrologix Biotech, Inc.	Anti-viral 7-deaza l-nucleosides
JP2005525358A (ja) *	2002-02-28	2005-08-25	ビオタインコーポレーティッド	ヌクレオチド模倣体およびそのプロドラッグ
BR0311141A (pt) *	2002-06-27	2005-06-07	Medivir Ab	Interação sinergìstica de abacavir e alovudine
US7608600B2 (en) *	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172993A (zh) *	2002-06-28	2008-05-07	埃迪尼克斯(开曼)有限公司	用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
EP2799442A1 (en)	2002-06-28	2014-11-05	IDENIX Pharmaceuticals, Inc.	Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections
KR20050055630A (ko)	2002-06-28	2005-06-13	이데닉스 (케이만) 리미티드	플라비비리다에 감염 치료를 위한 1'-, 2'- 및 3'-변형된뉴클레오시드 유도체
PL374781A1 (en) *	2002-06-28	2005-10-31	Idenix (Cayman) Limited	2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TWI244393B (en) *	2002-08-06	2005-12-01	Idenix Pharmaceuticals Inc	Crystalline and amorphous forms of beta-L-2'-deoxythymidine
SI1572095T1 (sl) *	2002-09-13	2015-12-31	Novartis Ag	Beta-l-2'-deoksinukleozidi za uporabo pri zdravljenju odpornih sevov hbv
MXPA05004503A (es)	2002-10-31	2005-08-16	Metabasis Therapeutics Inc	Nuevos profarmacos de monofosfato de citarabina.
PL377342A1 (pl) *	2002-11-15	2006-01-23	Idenix (Cayman) Limited	Nukleozydy rozgałęzione w pozycji 2' oraz mutacja Flaviviridae
PL377287A1 (pl) *	2002-12-12	2006-01-23	Idenix (Cayman) Limited	Sposób wytwarzania 2'-rozgałęzionych nukleozydów
KR20060008297A (ko)	2003-03-20	2006-01-26	마이크로 바이올로지카 퀴미카 이 파마슈티카 리미티드	2'-데옥시-β-Ｌ-뉴클레오시드의 제조방법
WO2004096149A2 (en) *	2003-04-28	2004-11-11	Idenix (Cayman) Limited	Industrially scalable nucleoside synthesis
WO2004096197A2 (en) *	2003-05-02	2004-11-11	Universita Degli Studi Di Cagliari	5-aza-7-deazapurine nucleosides for treating flaviviridae
TR201906767T4 (tr)	2003-05-30	2019-05-21	Gilead Pharmasset Llc	Modifiye florlanmış nükleosit analogları.
AU2004254620A1 (en)	2003-06-30	2005-01-13	Idenix (Cayman) Limited	Synthesis of beta-L-2-deoxy nucleosides
CN1315863C (zh) *	2003-12-12	2007-05-16	河南省科学院质量检验与分析测试研究中心	β－L－2'－脱氧－核苷衍生物、其合成方法及其药物用途
SG158136A1 (en)	2004-09-14	2010-01-29	Pharmasset Inc	Preparation of 2`-fluoro-2`- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP4516863B2 (ja) *	2005-03-11	2010-08-04	株式会社ケンウッド	音声合成装置、音声合成方法及びプログラム
US8076303B2 (en)	2005-12-13	2011-12-13	Spring Bank Pharmaceuticals, Inc.	Nucleotide and oligonucleotide prodrugs
US7781576B2 (en) *	2005-12-23	2010-08-24	Idenix Pharmaceuticals, Inc.	Process for preparing a synthetic intermediate for preparation of branched nucleosides
ES2543840T3 (es)	2006-04-11	2015-08-24	Novartis Ag	Inhibidores espirocíclicos del VHC/VIH y sus usos
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
US20090082306A1 (en) *	2007-09-26	2009-03-26	Protia, Llc	Deuterium-enriched telbivudine
TW200946541A (en)	2008-03-27	2009-11-16	Idenix Pharmaceuticals Inc	Solid forms of an anti-HIV phosphoindole compound
EP2376515A1 (en)	2008-12-23	2011-10-19	Pharmasset, Inc.	Synthesis of purine nucleosides
KR20110098849A (ko)	2008-12-23	2011-09-01	파마셋 인코포레이티드	뉴클레오시드 유사체
ES2623016T3 (es)	2008-12-23	2017-07-10	Gilead Pharmasset Llc	Fosforamidatos de nucleósido de 2-amino purina 6-O-sustituida
US20110182850A1 (en)	2009-04-10	2011-07-28	Trixi Brandl	Organic compounds and their uses
US8512690B2 (en)	2009-04-10	2013-08-20	Novartis Ag	Derivatised proline containing peptide compounds as protease inhibitors
TWI576352B (zh)	2009-05-20	2017-04-01	基利法瑪席特有限責任公司	核苷磷醯胺
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
AU2010319999B2 (en) *	2009-11-16	2014-01-16	University Of Georgia Research Foundation, Inc.	2'-Fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
UA122959C2 (uk)	2010-03-31	2021-01-27	Гайлід Фармассет Елелсі	Нуклеозидфосфорамідати
JP5909495B2 (ja)	2010-10-08	2016-04-26	ノバルティスアーゲー	スルファミドｎｓ３阻害剤のビタミンｅ製剤
JP6069215B2 (ja)	2010-11-30	2017-02-01	ギリアドファーマセットエルエルシー	化合物
CN102649788B (zh) *	2011-02-28	2015-03-25	四川大学	β-L-2’-脱氧-胸腺嘧啶核苷衍生物及其制备方法和用途
EP2709613B2 (en)	2011-09-16	2020-08-12	Gilead Pharmasset LLC	Methods for treating hcv
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
US20140212491A1 (en)	2013-01-31	2014-07-31	Gilead Pharmasset Llc	Combination formulation of two antiviral compounds
EP3038601B1 (en)	2013-08-27	2020-04-08	Gilead Pharmasset LLC	Combination formulation of two antiviral compounds
CN114404427A (zh)	2014-02-13	2022-04-29	配体药物公司	前药化合物及其用途
US9994600B2 (en)	2014-07-02	2018-06-12	Ligand Pharmaceuticals, Inc.	Prodrug compounds and uses therof
AU2019207625A1 (en)	2018-01-09	2020-07-30	Ligand Pharmaceuticals, Inc.	Acetal compounds and therapeutic uses thereof
CN110680806A (zh) *	2018-07-04	2020-01-14	郑州泰丰制药有限公司	一种替比夫定颗粒的制备方法
CN108570078A (zh) *	2018-07-18	2018-09-25	荆门医药工业技术研究院	一种制备1-O-乙酰基-2,3,5-三-O-苯甲酰基-β-D-呋喃核糖的方法
CN114133398B (zh) *	2021-12-31	2022-11-22	中南民族大学	氨基酸取代的阿昔洛韦类三环核苷衍生物及其合成方法和应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB875971A (en)	1959-01-14	1961-08-30	Hoffmann La Roche	A process for the manufacture of uridine and thymidine derivatives and novel compounds concerned therein
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5223263A (en)	1988-07-07	1993-06-29	Vical, Inc.	Liponucleotide-containing liposomes
US4916122A (en)	1987-01-28	1990-04-10	University Of Georgia Research Foundation, Inc.	3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5190926A (en)	1987-01-28	1993-03-02	University Of Georgia Research Foundation, Inc.	3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
GB8719367D0 (en)	1987-08-15	1987-09-23	Wellcome Found	Therapeutic compounds
WO1989002733A1 (en)	1987-09-22	1989-04-06	The Regents Of The University Of California	Liposomal nucleoside analogues for treating aids
KR890701609A (ko)	1987-10-28	1989-12-21	원본미기재	아실 데옥시리보뉴클레오시드 유도체 및 그의 사용
US6020322A (en)	1993-11-09	2000-02-01	Pro-Neuron, Inc.	Acyl deoxyribonucleoside derivatives and uses thereof
JP2675864B2 (ja)	1988-07-05	1997-11-12	キヤノン株式会社	被記録材及びこれを用いたインクジェット記録方法
SE8802687D0 (sv) *	1988-07-20	1988-07-20	Astra Ab	Nucleoside derivatives
US5194654A (en)	1989-11-22	1993-03-16	Vical, Inc.	Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en)	1989-06-28	1995-05-02	Vestar, Inc.	Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en)	1989-11-22	1995-10-31	Vestar, Inc.	Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5204466A (en)	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
AU7872491A (en)	1990-05-07	1991-11-27	Vical, Inc.	Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
WO1991018914A1 (en)	1990-05-29	1991-12-12	Vical, Inc.	Synthesis of glycerol di- and triphosphate derivatives
JP3347723B2 (ja)	1990-06-13	2002-11-20	グラツィエル，アーノルド	含リンプロドラッグ
EP0543806B1 (en)	1990-07-12	1996-01-17	G-Drill Ab	Hydraulic down-the-hole rock drill
ATE167679T1 (de) *	1990-09-14	1998-07-15	Acad Of Science Czech Republic	Wirkstoffvorläufer von phosphonaten
US5206244A (en) *	1990-10-18	1993-04-27	E. R. Squibb & Sons, Inc.	Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
US5256641A (en)	1990-11-01	1993-10-26	State Of Oregon	Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en)	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Covalent microparticle-drug conjugates for biological targeting
US5543389A (en)	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization	Covalent polar lipid-peptide conjugates for use in salves
US5149794A (en)	1990-11-01	1992-09-22	State Of Oregon	Covalent lipid-drug conjugates for drug targeting
IT1246983B (it)	1990-11-13	1994-12-12	Consiglio Nazionale Ricerche	L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
IL100502A (en)	1991-01-03	1995-12-08	Iaf Biochem Int	PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
EP1808434A3 (en)	1991-03-06	2008-04-02	Emory University	Use of 5-fluoro-2'-deoxy-3'-thiacytidine fo the treatment of hepatitis B
US5220003A (en)	1991-03-29	1993-06-15	The Regents Of The University Of California	Process for the synthesis of 2',3'-dideoxynucleosides
WO1992018517A1 (en)	1991-04-17	1992-10-29	Yale University	Method of treating or preventing hepatitis b virus
EP0594677A4 (en)	1991-07-12	1997-09-17	Vical Inc	Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en)	1991-07-23	1996-09-10	Nexstar Pharmaceuticals, Inc.	Lipid conjugates of therapeutic peptides and protease inhibitors
EP0691981A1 (en) *	1993-03-10	1996-01-17	The Wellcome Foundation Limited	Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides
JP3693357B2 (ja)	1993-04-09	2005-09-07	峯郎実吉	逆転写酵素阻害剤
EP0746319A4 (en)	1993-05-12	1997-11-05	Karl Y Hostetler	ACYCLOVIR DERIVATIVES FOR TOPICAL USE
US5627160A (en) *	1993-05-25	1997-05-06	Yale University	L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
WO1995007086A1 (en)	1993-09-10	1995-03-16	Emory University	Nucleosides with anti-hepatitis b virus activity
US5587362A (en)	1994-01-28	1996-12-24	Univ. Of Ga Research Foundation	L-nucleosides
WO1996011204A1 (de) *	1994-10-07	1996-04-18	Max-Delbrück-Centrum für Molekulare Medizin	NEUE β-L-NUCLEOSIDE UND IHRE VERWENDUNG
US5559101A (en) *	1994-10-24	1996-09-24	Genencor International, Inc.	L-ribofuranosyl nucleosides
US5696277A (en)	1994-11-15	1997-12-09	Karl Y. Hostetler	Antiviral prodrugs
EP0831852B1 (en) *	1995-06-07	2006-11-29	Emory University	Nucleosides with anti-hepatitis b virus activity
US6025335A (en) *	1995-09-21	2000-02-15	Lipitek International, Inc.	L-Nucleoside Dimer Compounds and therapeutic uses
EP1069903A1 (en)	1998-03-11	2001-01-24	Lipitek International, Inc.	Novel nucleoside analogs and uses in treating disease
MXPA00012842A (es)	1998-06-24	2004-06-22	Univ Emory	Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
DE122007000062I1 (de) *	1998-08-10	2007-12-20	Idenix Cayman Ltd	Beta-L-2'-deoxynukleoside für die Behandlung von Hepatitis-B-Virus
US6444652B1 (en) *	1998-08-10	2002-09-03	Novirio Pharmaceuticals Limited	β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
MY164523A (en) *	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
AP2006003708A0 (en) *	2000-05-26	2006-08-31	Idenix Cayman Ltd	Methods and compositions for treating flavivirusesand pestiviruses
ES2227203T3 (es) *	2000-05-26	2005-04-01	Idenix (Cayman) Limited	Metodos para tratar la infeccion por el virus de la hepatitis delta con beta-1-2'-desoxinucleosidos.
US6787526B1 (en) *	2000-05-26	2004-09-07	Idenix Pharmaceuticals, Inc.	Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides

1999
- 1999-08-10 DE DE200712000062 patent/DE122007000062I1/de active Pending
- 1999-08-10 CN CNB998095532A patent/CN1257912C/zh not_active Expired - Lifetime
- 1999-08-10 KR KR1020067007301A patent/KR100691737B1/ko not_active IP Right Cessation
- 1999-08-10 KR KR1020067007304A patent/KR100702230B1/ko not_active IP Right Cessation
- 1999-08-10 AT AT99941027T patent/ATE313550T1/de active
- 1999-08-10 DK DK10184657.4T patent/DK2415776T3/en active
- 1999-08-10 CN CNB021265739A patent/CN100482236C/zh not_active Expired - Lifetime
- 1999-08-10 US US09/371,747 patent/US6395716B1/en not_active Expired - Lifetime
- 1999-08-10 RU RU2006147216/04A patent/RU2424016C2/ru active Protection Beyond IP Right Term
- 1999-08-10 JP JP2000564981A patent/JP4294870B2/ja not_active Expired - Lifetime
- 1999-08-10 WO PCT/US1999/018149 patent/WO2000009531A2/en active IP Right Grant
- 1999-08-10 MX MXPA01001507A patent/MXPA01001507A/es active IP Right Grant
- 1999-08-10 EP EP99941027A patent/EP1104436B1/en not_active Expired - Lifetime
- 1999-08-10 CN CNB2004100028639A patent/CN100387237C/zh not_active Expired - Lifetime
- 1999-08-10 ES ES99941027T patent/ES2255295T3/es not_active Expired - Lifetime
- 1999-08-10 DE DE69929060T patent/DE69929060T2/de not_active Expired - Lifetime
- 1999-08-10 PT PT4075926T patent/PT1431304E/pt unknown
- 1999-08-10 KR KR1020017001758A patent/KR100634342B1/ko active IP Right Grant
- 1999-08-10 DK DK04075926T patent/DK1431304T3/en active
- 1999-08-10 ES ES04075926.8T patent/ES2531928T3/es not_active Expired - Lifetime
- 1999-08-10 BR BRPI9912896A patent/BRPI9912896B8/pt not_active IP Right Cessation
- 1999-08-10 ES ES10184657.4T patent/ES2579903T3/es not_active Expired - Lifetime
- 1999-08-10 CA CA002340156A patent/CA2340156C/en not_active Expired - Lifetime
- 1999-08-10 PT PT101846574T patent/PT2415776T/pt unknown
- 1999-08-10 SG SG200302078-1A patent/SG132498A1/en unknown
- 1999-08-10 DK DK99941027T patent/DK1104436T3/da active
- 1999-08-10 EP EP10184657.4A patent/EP2415776B1/en not_active Expired - Lifetime
- 1999-08-10 KR KR1020057009515A patent/KR100568035B1/ko not_active IP Right Cessation
- 1999-08-10 AU AU54757/99A patent/AU5475799A/en not_active Abandoned
2001
- 2001-06-26 HK HK01104418A patent/HK1034083A1/xx not_active IP Right Cessation
- 2001-12-14 US US10/022,276 patent/US6569837B1/en not_active Expired - Lifetime
2003
- 2003-05-13 US US10/438,167 patent/US20030225028A1/en not_active Abandoned
2005
- 2005-09-22 US US11/232,818 patent/US7304043B2/en not_active Expired - Lifetime
2007
- 2007-05-07 JP JP2007122896A patent/JP2007269798A/ja active Pending
- 2007-05-21 HK HK07105364.0A patent/HK1097776A1/xx not_active IP Right Cessation
- 2007-07-18 LU LU91348C patent/LU91348I2/fr unknown
- 2007-08-06 CY CY200700017C patent/CY2007017I1/el unknown
- 2007-08-09 NL NL300286C patent/NL300286I2/nl unknown
- 2007-09-21 FR FR07C0046C patent/FR07C0046I2/fr active Active
- 2007-10-30 US US11/929,807 patent/US20080064655A1/en not_active Abandoned
2008
- 2008-06-24 HK HK08107009.6A patent/HK1111913A1/xx not_active IP Right Cessation
2015
- 2015-03-02 CY CY20151100218T patent/CY1116988T1/el unknown

Also Published As

Publication number	Publication date
KR100691737B1 (ko)	2007-03-12
CY2007017I2 (el)	2009-11-04
RU2424016C2 (ru)	2011-07-20
KR100634342B1 (ko)	2006-10-16
JP2007269798A (ja)	2007-10-18
KR20050062664A (ko)	2005-06-23
EP2415776B1 (en)	2016-05-25
SG132498A1 (en)	2007-06-28
RU2006147216A (ru)	2008-07-10
US20080064655A1 (en)	2008-03-13
US20060084624A1 (en)	2006-04-20
KR100702230B1 (ko)	2007-04-03
BRPI9912896B8 (pt)	2021-05-25
ATE313550T1 (de)	2006-01-15
AU5475799A (en)	2000-03-06
CY1116988T1 (el)	2017-04-05
MXPA01001507A (es)	2003-09-10
NL300286I2 (nl)	2008-01-02
KR20010072392A (ko)	2001-07-31
FR07C0046I1 (nl)	2007-10-26
WO2000009531A2 (en)	2000-02-24
DE69929060T2 (de)	2006-08-31
US6395716B1 (en)	2002-05-28
LU91348I9 (nl)	2018-12-31
US20030225028A1 (en)	2003-12-04
KR20060035817A (ko)	2006-04-26
JP2002522552A (ja)	2002-07-23
CA2340156A1 (en)	2000-02-24
FR07C0046I2 (fr)	2008-05-09
US6569837B1 (en)	2003-05-27
CA2340156C (en)	2007-10-23
EP2415776A1 (en)	2012-02-08
WO2000009531A3 (en)	2000-06-15
DE122007000062I1 (de)	2007-12-20
ES2255295T3 (es)	2006-06-16
ES2531928T3 (es)	2015-03-20
CN100387237C (zh)	2008-05-14
BRPI9912896B1 (pt)	2016-08-09
JP4294870B2 (ja)	2009-07-15
KR20060038483A (ko)	2006-05-03
EP1104436B1 (en)	2005-12-21
KR100568035B1 (ko)	2006-04-07
PT1431304E (pt)	2015-03-09
CY2007017I1 (el)	2009-11-04
CN1320128A (zh)	2001-10-31
LU91348I2 (fr)	2007-09-18
CN100482236C (zh)	2009-04-29
HK1111913A1 (en)	2008-08-22
ES2579903T3 (es)	2016-08-17
HK1034083A1 (en)	2001-10-12
CN1478483A (zh)	2004-03-03
CN1257912C (zh)	2006-05-31
HK1097776A1 (en)	2007-07-06
CN1606983A (zh)	2005-04-20
DK2415776T3 (en)	2016-07-04
DK1104436T3 (da)	2006-04-03
DE69929060D1 (de)	2006-01-26
BR9912896A (pt)	2002-02-13
EP1104436A2 (en)	2001-06-06
US7304043B2 (en)	2007-12-04
DK1431304T3 (en)	2015-03-02
PT2415776T (pt)	2016-07-07

Publication	Publication Date	Title
NL300286I1 (nl)	2007-10-01	Beta-l-2'-desoxynucleosiden voor de behandeling van heparitis-b-virus
AR035711A1 (es)	2004-07-07	Prodrogas 3' de 2'-desoxi-beta-l-nucleosidos; sus composiciones farmaceuticas; metodo para el tratamiento o profilaxis de una infeccion del virus de la hepatitis b y sus usos para la manufactura de composiciones farmaceuticas
CY1112254T1 (el)	2015-12-09	Αρυλικοι φωσφοραμιδικοι εστερες νουκλεοζιτων και οι χρησεις τους ως αντι-ιικοι παραγοντες για την αντιμετωπιση του ιου της ηπατιτιδας c
ES2115918T3 (es)	1998-07-01	Nucleosidos de beta-d-dioxolano de pureza enantiomera y de actividad dirigida selectivamente contra el virus de la hepatitis b.
PA8483101A1 (es)	2000-09-29	Compuestos quimicos
ATE115958T1 (de)	1995-01-15	Nukleoside und nukleosid-analoge, pharmazeutische zusammensetzung und verfahren für die herstellung der bestandteile.
ATE157252T1 (de)	1997-09-15	3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
HK1036069A1 (en)	2001-12-21	Nucleosides with anti-hepatitis b virus activity
KR890003384A (ko)	1989-04-14	B형 간염의 항 비루스 치료방법 및 조성물
KR950701638A (ko)	1995-04-28	푸린 동족체의 항비루스성 포스폰산 유도체(Antiviral phosphonic acid derivatives of purine analogues)
HU901252D0 (en)	1990-05-28	Process for manufacturing of pharmaceutical compositions comprising purine derivatives
HUT37439A (en)	1985-12-28	Process for production of derivatives of phosphorilized glucose-amidcarbamide-carbamate and tiocarbamate and medical preparatives consisting of such substances
CY1117836T1 (el)	2017-05-17	Βητα-l-2'-δεοξυ-νουκλεοσιδια για την θεραπεια ηπατιτιδας β
RU2001106651A (ru)	2003-04-20	Бета-l-2 - дезокси-нуклеотиды для лечения гепатита в
ATE321561T1 (de)	2006-04-15	Azidoderivate von beta-l-2'-nukleosiden zur hiv- infektionsbehandlung
YU221289A (en)	1991-02-28	Antivirus compounds
RU2001115094A (ru)	2003-03-10	Нуклеозиды, обладающие активностью против вируса гепатита в
MX9704336A (es)	1997-09-30	Uso de agentes antivirales para el tratamiento y profilaxis de infecciones latentes de herpesvirus.